abdallah al-hakim
Senior Director of Revenue Operations and Demand Generation Strategy at Armorblox
senior director revenue operation demand generation strategy armorblox
experienced manager cloud technology integration drive key initiative execute strategic operational objective . experience ha allowed insight across revenue operation component company early rapid accelerated growth phase . passionate combining technology strategy business operation execute key program . driven challenge solve complex problem innovative way avoid ( necessary ) standard approach line thinking .
Armorblox
https://www.linkedin.com/company/armorbloxinc
San Jose, California, United States
https://media-exp1.licdn.com/dms/image/C4D0BAQHWh14EOARs_Q/company-logo_100_100/0/1625701787691?e=1655942400&v=beta&t=deXB2tGAXUrn4d5x-SuGUnEEOFSi5a_-oLJqVsPcXjs
Senior Director of Revenue Operations and Demand Generation Strategy
Armorblox
https://www.linkedin.com/company/armorbloxinc
https://media-exp1.licdn.com/dms/image/C4D0BAQHWh14EOARs_Q/company-logo_100_100/0/1625701787691?e=1655942400&v=beta&t=deXB2tGAXUrn4d5x-SuGUnEEOFSi5a_-oLJqVsPcXjs
Director of Revenue Operations & Demand Generation Strategy
BlueJeans Network
https://www.linkedin.com/company/bluejeans-by-verizon
I lead the Systems and Infrastructure team at BlueJeans. My team works on automating & designing scalable system architecture for acquiring & retaining customers. We are responsible for building the required integrations across the various third party SaaS tools to drive more value to the company and our internal users.
Mountain View, California
https://media-exp1.licdn.com/dms/image/C4E0BAQFs4nsWQci0_Q/company-logo_100_100/0/1589773091231?e=1655942400&v=beta&t=0Xlu7G6vIsqytVLklcdal2MlNnH7RemL50jI_VBqnpo
Senior Manager: Business Systems and Operations
BlueJeans Network
https://www.linkedin.com/company/bluejeans-by-verizon
Toronto, Canada Area
https://media-exp1.licdn.com/dms/image/C4E0BAQFs4nsWQci0_Q/company-logo_100_100/0/1589773091231?e=1655942400&v=beta&t=0Xlu7G6vIsqytVLklcdal2MlNnH7RemL50jI_VBqnpo
Marketing Operations Manager
Influitive
https://www.linkedin.com/company/influitive
Marketing operations manager for Influitive, leader in emerging advocate marketing space. Responsible for strategy and execution of all aspects of marketing operations, including: campaign management, data management, lead management, website management.

- I play a critical role with the Demand Generation team to maximize their use of our marketing tools and platforms
- I work closely with the marketing team to develop and execute segmented and targeted lead generation campaigns
- I collaborate with sales team to coordinate marketing-to-sales lead handoff and in the process build an excellent alignment between marketing and sales.
- I helped develop and implement our marketing analytics and reporting dashboards to allow the team to measure all aspects including data cleanliness, campaign effectiveness, marketing funnel conversions and other key strategic goals.
- Together with the sales team, I assisted in building our account based marketing strategy and identifying key target accounts and contacts.
- I managed the website to fully integrate with marketing automation platform and executed SEO strategy to increase lead generation from inbound sources.
Toronto
https://media-exp1.licdn.com/dms/image/C560BAQGwLbxHY9ToXA/company-logo_100_100/0/1568060558920?e=1655942400&v=beta&t=1_a8XnamCljmPsYBmgVpQxMoCrSngSDVjy-ea-Pw_Pc
Marketing Operations Specialist
Engagio
•Social Media monitoring: Routinely use tools such as Mention, Commun.it, Topsy, Prismatic, Buffer, Bit.ly to monitor social media mentions. 
•Marketing: Organized email marketing campaigns using MailChimp and SendGrid. I have prepared templates by using WYSIWYG and/or HTML editor
•Analytics: Prepared weekly metrics reports using statistics from Woopra and Google analytics applications. Setup custom campaigns with unique URLs to track in Woopra and Google analytics
•Brand advocate: Routinely discover and engage in social conversations on the web and promote Engagio where appropriate.
•Search Engine Optimization (SEO): Familiar with the Seomoz and Raven tooll applications to organize SEO campaigns 
•Website management: Monitoring and analyzing traffic metrics related to the website using Google webmaster tools
Toronto, Canada Area
Marketing & Online community manager
ReadyPortal
https://www.linkedin.com/company/readyportal
•Communication: Setup a blog site and contributed weekly content to establish the company as a thought leader – authored an article in CMSwire, a leading software publishing online website
•Marketing: Developed social media strategy and web analytics process
•Presentation: Prepared and advised on investor pitch to venture capitalists for $500K round of capital
•Business development: Involved in the setup and negotiations towards a number of business partnerships
Toronto, Canada Area
https://media-exp1.licdn.com/dms/image/C4E0BAQFB2Z8j1NC4kQ/company-logo_100_100/0/1519883216601?e=1655942400&v=beta&t=48w7R2e1D8f2w9nfzAivKAaHx-lpbuKUMyxLKyE7M5U
Product Strategist
Samuel Lunenfeld Research Institute
https://www.linkedin.com/company/university-of-toronto-mount-sinai-hospital
•	Project management skills:  Successfully led 5 different research projects through different stages of development 
•	Teamwork and leadership skills: Supervised 2 graduate students and am actively involved in the co-supervision of 5 other students
•	Operations skills: Developed new skills and optimize current research processes
•	Organizational skills: Involved in setting laboratory strategy and communicating research goals to collaborators
•	Communication skills: Extensive experience in preparing oral and written reports 
•	Successfully authored and published numerous scientific articles in top-tier peer-reviewed international journals
Toronto, Canada Area
CIHR & TD Postdoctoral Research Fellow
MRC protein phosphorylation Institute
•	Managed to completion a number of team-based projects
•	Participated in four quarterly meetings of the Planning for Management Committee which is a consortium of 5 pharmaceutical companies (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck-Serono and Pfizer) where I offered expert advise on the potential of drug development in my respective area of research
•	Developed strong public speaking skills by presenting my findings in a number of public events
•	Trained numerous researchers and taught undergraduate students
Dundee, United Kingdom
Ph.D candidate
Banting and Best Research Institute
•	Developed team-based skills by working on collaborative projects
•	Developed organizational and operation skills as the elected representative to the Graduate Student council
Toronto, Canada Area
M.Sc. candidate
Ph.D
Laboratory of Professor Dario Alessi
Biochemistry
https://media-exp1.licdn.com/dms/image/C4D0BAQEmvT2aAE8Q3g/company-logo_100_100/0/1622634970968?e=1655942400&v=beta&t=aDK71cdFJWm9lBP3U-RKHRzRVbWuznkbvZiU0Df7P04
University of Dundee
https://www.linkedin.com/school/universityofdundee/
M.Sc.
Laboratory of Professor Bernard Schimmer
Pharmacology
https://media-exp1.licdn.com/dms/image/C4D0BAQHX-foiyEDxpw/company-logo_100_100/0/1639421285415?e=1655942400&v=beta&t=YiP7C6HtAsZtvXppKqN_qjOGts-iTDJABK7BCpJ9qPU
University of Toronto
https://www.linkedin.com/school/university-of-toronto/
Master of Science (MSc)
Pharmacology
https://media-exp1.licdn.com/dms/image/C4D0BAQHX-foiyEDxpw/company-logo_100_100/0/1639421285415?e=1655942400&v=beta&t=YiP7C6HtAsZtvXppKqN_qjOGts-iTDJABK7BCpJ9qPU
University of Toronto
https://www.linkedin.com/school/university-of-toronto/
B.Sc.
graduated with high distinction
Cell and Molecular biology
https://media-exp1.licdn.com/dms/image/C4D0BAQHX-foiyEDxpw/company-logo_100_100/0/1639421285415?e=1655942400&v=beta&t=YiP7C6HtAsZtvXppKqN_qjOGts-iTDJABK7BCpJ9qPU
University of Toronto
https://www.linkedin.com/school/university-of-toronto/
The CRAPome: a contaminant repository for affinity purification–mass spectrometry data
NATURE METHODS
http://www.nature.com/nmeth/journal/v10/n8/abs/nmeth.2557.html
Interaction Proteomics Identify NEURL4 and the HECT E3 Ligase HERC2 as Novel Modulators of Centrosome Architecture
Mol Cell Proteomics
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433907/
Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the HECT family E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high-resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNAi-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on non-overlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2 and together, these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.
Interaction proteomics identify NEURL4 and the HECT E3 ligase HERC2 as novel modulators of centrosome architecture
Molecular and Cellular Proteomics
http://www.mcponline.org/content/early/2012/01/19/mcp.M111.014233.abstract
In the ubiquitin-proteasome system (UPS), E2 enzymes mediate the conjugation of ubiquitin to substrates and thereby control protein stability and interactions. The E2 enzyme hCdc34 catalyzes the ubiquitination of hundreds of proteins in conjunction with the cullin-RING (CRL) superfamily of E3 enzymes. We identified a small molecule termed CC0651 that selectively inhibits hCdc34. Structure determination revealed that CC0651 inserts into a cryptic binding pocket on hCdc34 distant from the catalytic site, causing subtle but wholesale displacement of E2 secondary structural elements. CC0651 analogs inhibited proliferation of human cancer cell lines and caused accumulation of the SCF(Skp2) substrate p27(Kip1). CC0651 does not affect hCdc34 interactions with E1 or E3 enzymes or the formation of the ubiquitin thioester but instead interferes with the discharge of ubiquitin to acceptor lysine residues. E2 enzymes are thus susceptible to noncatalytic site inhibition and may represent a viable class of drug target in the UPS.
An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.
Cell
http://www.ncbi.nlm.nih.gov/pubmed/21683433
Protein ubiquitylation has emerged as an important regulatory mechanism that impacts almost every aspect of the DNA damage response. In this review, we discuss how DNA repair and checkpoint pathways utilize the diversity offered by the ubiquitin conjugation system to modulate the response to genotoxic lesions in space and time. In particular, we will highlight recent work done on the regulation of DNA double-strand breaks signalling and repair by the RNF8/RNF168 E3 ubiquitin ligases, the Fanconi anemia pathway and the role of protein degradation in the enforcement and termination of checkpoint signalling. We also discuss the various functions of deubiquitylating enzymes in these processes along with potential avenues for exploiting the ubiquitin conjugation/deconjugation system for therapeutic purposes.
The ubiquitous role of ubiquitin in the DNA damage response.
DNA Repair
http://www.ncbi.nlm.nih.gov/pubmed/21056014
Genome integrity is jeopardized each time DNA replication forks stall or collapse. Here we report the identification of a complex composed of MMS22L (C6ORF167) and TONSL (NFKBIL2) that participates in the recovery from replication stress. MMS22L and TONSL are homologous to yeast Mms22 and plant Tonsoku/Brushy1, respectively. MMS22L-TONSL accumulates at regions of ssDNA associated with distressed replication forks or at processed DNA breaks, and its depletion results in high levels of endogenous DNA double-strand breaks caused by an inability to complete DNA synthesis after replication fork collapse. Moreover, cells depleted of MMS22L are highly sensitive to camptothecin, a topoisomerase I poison that impairs DNA replication progression. Finally, MMS22L and TONSL are necessary for the efficient formation of RAD51 foci after DNA damage, and their depletion impairs homologous recombination. These results indicate that MMS22L and TONSL are genome caretakers that stimulate the recombination-dependent repair of stalled or collapsed replication forks.
The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination.
Molecular Cell
http://www.ncbi.nlm.nih.gov/pubmed/21055983
DNA double-strand breaks (DSBs) pose a potent threat to genome integrity. These lesions also contribute to the efficacy of radiotherapy and many cancer chemotherapeutics. DSBs elicit a signalling cascade that modifies the chromatin surrounding the break, first by ATM-dependent phosphorylation and then by RNF8-, RNF168- and BRCA1-dependent regulatory ubiquitination. Here we report that OTUB1, a deubiquitinating enzyme, is an inhibitor of DSB-induced chromatin ubiquitination. Surprisingly, we found that OTUB1 suppresses RNF168-dependent poly-ubiquitination independently of its catalytic activity. OTUB1 does so by binding to and inhibiting UBC13 (also known as UBE2N), the cognate E2 enzyme for RNF168. This unusual mode of regulation is unlikely to be limited to UBC13 because analysis of OTUB1-associated proteins revealed that OTUB1 binds to E2s of the UBE2D and UBE2E subfamilies. Finally, OTUB1 depletion mitigates the DSB repair defect associated with defective ATM signalling, indicating that pharmacological targeting of the OTUB1-UBC13 interaction might enhance the DNA damage response.
Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1.
Nature
http://www.ncbi.nlm.nih.gov/pubmed/20725033
The biological response to DNA double-strand breaks acts to preserve genome integrity. Individuals bearing inactivating mutations in components of this response exhibit clinical symptoms that include cellular radiosensitivity, immunodeficiency, and cancer predisposition. The archetype for such disorders is Ataxia-Telangiectasia caused by biallelic mutation in ATM, a central component of the DNA damage response. Here, we report that the ubiquitin ligase RNF168 is mutated in the RIDDLE syndrome, a recently discovered immunodeficiency and radiosensitivity disorder. We show that RNF168 is recruited to sites of DNA damage by binding to ubiquitylated histone H2A. RNF168 acts with UBC13 to amplify the RNF8-dependent histone ubiquitylation by targeting H2A-type histones and by promoting the formation of lysine 63-linked ubiquitin conjugates. These RNF168-dependent chromatin modifications orchestrate the accumulation of 53BP1 and BRCA1 to DNA lesions, and their loss is the likely cause of the cellular and developmental phenotypes associated with RIDDLE syndrome.
The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage.
Cell
http://www.ncbi.nlm.nih.gov/pubmed/19203578
AMPK (AMP-activated protein kinase)-related kinases regulate cell polarity as well as proliferation and are activated by the LKB1-tumour suppressor kinase. In the present study we demonstrate that the AMPK-related kinases, NUAK1 (AMPK-related kinase 5) and MARK4 (microtubule-affinity-regulating kinase 4), are polyubiquitinated in vivo and interact with the deubiquitinating enzyme USP9X (ubiquitin specific protease-9). Knockdown of USP9X increased polyubiquitination of NUAK1 and MARK4, whereas overexpression of USP9X inhibited ubiquitination. USP9X, catalysed the removal of polyubiquitin chains from wild-type NUAK1, but not from a non-USP9X-binding mutant. Topological analysis revealed that ubiquitin monomers attached to NUAK1 and MARK4 are linked by Lys(29) and/or Lys(33) rather than the more common Lys(48)/Lys(63). We find that AMPK and other AMPK-related kinases are also polyubiquitinated in cells. We identified non-USP9X-binding mutants of NUAK1 and MARK4 and find that these are hyper-ubiquitinated and not phosphorylated at their T-loop residue targeted by LKB1 when expressed in cells, suggesting that polyubiquitination may inhibit these enzymes. The results of the present study demonstrate that NUAK1 and MARK4 are substrates of USP9X and provide the first evidence that AMPK family kinases are regulated by unusual Lys(29)/Lys(33)-linked
Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains.
Biochemical Journal
http://www.ncbi.nlm.nih.gov/pubmed/18254724
The LKB1 tumour suppressor kinase phosphorylates and activates a number of protein kinases belonging to the AMP-activated protein kinase (AMPK) subfamily. We have used a modified tandem affinity purification strategy to identify proteins that interact with AMPKalpha, as well as the twelve AMPK-related kinases that are activated by LKB1. The AMPKbeta and AMPKgamma regulatory subunits were associated with AMPKalpha, but not with any of the AMPK-related kinases, explaining why AMP does not influence the activity of these enzymes. In addition, we identified novel binding partners that interacted with one or more of the AMPK subfamily enzymes, including fat facets/ubiquitin specific protease-9 (USP9), AAA-ATPase-p97, adenine nucleotide translocase, protein phosphatase 2A holoenzyme and isoforms of the phospho-protein binding adaptor 14-3-3. Interestingly, the 14-3-3 isoforms bound directly to the T-loop Thr residue of QSK and SIK, after these were phosphorylated by LKB1. Consistent with this, the 14-3-3 isoforms failed to interact with non-phosphorylated QSK and SIK, in LKB1 knockout muscle or in HeLa cells in which LKB1 is not expressed. Moreover, mutation of the T-loop Thr phosphorylated by LKB1, prevented QSK and SIK from interacting with 14-3-3 in vitro. Binding of 14-3-3 to QSK and SIK, enhanced catalytic activity towards the TORC2 protein and the AMARA peptide, and was required for the cytoplasmic localization of SIK and for localization of QSK to punctate structures within the cytoplasm. To our knowledge, this study provides the first example of 14-3-3 binding directly to the T-loop of a protein kinase and influencing its catalytic activity and cellular localization.
14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK.
Journal of Cell Science
http://www.ncbi.nlm.nih.gov/pubmed/16306228
Forskolin-resistant mutants of a mouse adrenocortical cell line present a complex phenotype in which adenylyl cyclase (AC) is resistant to activation by forskolin and by ACTH. ACTH-resistance results from a defect affecting transcription of the ACTH receptor and can be overcome by transfecting mutant cells with expression vectors encoding G beta/gamma. Forskolin-resistance results from an AC-4 deficiency. We now demonstrate that the AC-4 deficiency in forskolin-resistant mutants results from a transcription defect affecting the promoter activity of the AC-4 gene. Furthermore, the underlying defect leading to AC-4 deficiency and forskolin-resistance can be overcome by transfection of mutant clones with expression vectors encoding G beta/gamma. These data support our hypothesis that AC-4 is a preferred target of forskolin action in Y1 cells, demonstrate novel roles for G beta/gamma in gene expression and indicate that a common underlying defect, suppressible by G beta/gamma, accounts for both the resistance to ACTH and to forskolin.
Expression of adenylyl cyclase-4 (AC-4) in Y1 and forskolin-resistant adrenal cells.
Molecular and Cellular Endocrinology
http://www.ncbi.nlm.nih.gov/pubmed/15026181
Four mutant clones independently derived from the Y1 mouse adrenocortical tumor cell line have adenylyl cyclase (AC) activities that are resistant to forskolin, a direct activator of AC. In this study the AC isoform composition of the forskolin-resistant mutants was examined in order to explore the underlying basis for the resistance to forskolin. As determined by Western blot and RT-PCR analysis, the four forskolin-resistant mutants all were deficient in AC-4; the levels of other AC isoforms (AC-1, AC-3 and AC-5/6) were comparable to the levels in parent Y1 cells. Transfection of one of the mutant clones with an AC-4 expression vector increased forskolin-stimulated cAMP signaling, and restored forskolin-induced changes in cell morphology and growth. Taken together, these observations indicate that AC-4 deficiency is a hallmark of the forskolin-resistant phenotype of these mutants and suggest that AC-4 is an important target of forskolin action in the Y1 adrenal cell line.
Forskolin-resistant Y1 adrenal cell mutants are deficient in adenylyl cyclase type 4.
Molecular and Cellular Endocrinology
http://www.ncbi.nlm.nih.gov/pubmed/15062554
SiriusDecisions
Foundations of demand generation
http:///Users/abdallah/Desktop/Certificate_Foundations_Public_Final_Exam%20(1).pdf
https://www.linkedin.com/in/aramanathan
San Francisco Bay Area
Anand Ramanathan
SVP Products and Marketing at McAfee
https://www.linkedin.com/in/kerry-sanders-91a7695
New York, NY
Kerry Sanders
SVP Revenue Strategy, Operations and Enablement
https://ca.linkedin.com/in/josheasby
Canada
Josh Easby
Director, Revenue Enablement at HiMama
https://www.linkedin.com/in/anthonytianluo
Waltham, MA
Tian (Anthony) Luo
Master of Finance at Brandeis International Business School
https://www.linkedin.com/in/daniel-perez-b9b6659
Detroit Metropolitan Area
Daniel Perez
Director of Finance at Mode
https://www.linkedin.com/in/annelieu
San Francisco Bay Area
Anne Lieu
Sr. Product Manager, Sales Platform @ Visa
https://www.linkedin.com/in/chiquita-quintor
Fairfield, CA
Chiquita Q.
Senior Accountant
https://www.linkedin.com/in/jessicacortez32
Greater Sacramento
Jessica Cortez
Director, RevOps & Systems at Riskalyze
https://www.linkedin.com/in/randy-sexton-65b2b35
Lake Mary, FL
Randy Sexton
Sr. Sales Development Leader, AISM®- Leading highly productive sales professionals to the next level of their success.
https://www.linkedin.com/in/stephaniesallbailey
McLean, VA
Stephanie Sall Bailey
Vice President, Revenue Marketing at BetterUp
https://www.linkedin.com/in/jennifer-baker-marketing
Sacramento, CA
Jennifer Baker
Director, Growth Marketing
https://www.linkedin.com/in/melaniefellay
Denver, CO
Melanie Fellay 🐙
CEO at Spekit 🐙
https://www.linkedin.com/in/philrussell
Herndon, VA
Phil Russell
Sales executive focused on driving growth, scaling teams and enabling talent.
https://www.linkedin.com/in/tylerthovson
Scottsdale, AZ
Tyler Thovson
Manager, Sales - Mid Market at GRIN
https://www.linkedin.com/in/saleskickoffspeaker
Arlington, VA
Steve Richard
Founder @ ExecVision: Sales Coaching & Conversation Intelligence Software (202) 302-3193
https://www.linkedin.com/in/beccabycott
Washington, DC
Becca Bycott
Strategic Communications • Thought Leadership • Relationship Management
https://www.linkedin.com/in/timmcwhirk
Greater Sacramento
Tim McWhirk
VP, Customer Success at GRIN | WE'RE HIRING!
https://www.linkedin.com/in/johnathanwarren
Nashville Metropolitan Area
Johnathan Warren
Director of Revenue Operations
https://www.linkedin.com/in/patrickphelan
Little Rock, AR
Patrick Phelan
Senior Director of Growth Operations at Zenefits
https://www.linkedin.com/in/tyleratwell
Atlanta, GA
Tyler Atwell
VP of Revenue Operations @ Reibus
Liked by Abdallah Al-Hakim
https://www.linkedin.com/signup/cold-join
Congratulations to our Founder and Chief of Innovation and Products, Krish Ramakrishnan, who has been recognized by The CEO Forum Group for the 2021…
Liked by Abdallah Al-Hakim
https://www.linkedin.com/signup/cold-join
Complacency is the enemy of profitability for paid advertising.→ Not optimizing ad accounts consistently.→ Not refreshing creative frequently. →…
Liked by Abdallah Al-Hakim
https://www.linkedin.com/signup/cold-join
I really enjoyed giving my presentation and the follow-up Q&A discussion with the wonderful people at Altrusa International in Champaign!…